vs
Expensify, Inc.（EXFY）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
Expensify, Inc.的季度营收约是STANDARD BIOTOOLS INC.的1.8倍（$35.2M vs $19.6M），Expensify, Inc.同比增速更快（-4.9% vs -11.5%），过去两年Expensify, Inc.的营收复合增速更高（2.4% vs -12.2%）
Expensify Inc.是一家软件服务企业，主打面向个人与企业用户开发费用管理系统，助力用户便捷高效地完成费用报销、账单统计等工作，此外该公司还推出了名为Expensify Card的商务信用卡产品。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
EXFY vs LAB — 直观对比
营收规模更大
EXFY
是对方的1.8倍
$19.6M
营收增速更快
EXFY
高出6.6%
-11.5%
两年增速更快
EXFY
近两年复合增速
-12.2%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $35.2M | $19.6M |
| 净利润 | — | $-34.7M |
| 毛利率 | 49.2% | 48.5% |
| 营业利润率 | -11.2% | -168.5% |
| 净利率 | — | -177.4% |
| 营收同比 | -4.9% | -11.5% |
| 净利润同比 | — | -28.8% |
| 每股收益（稀释后） | $-0.07 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXFYLAB
| Q4 25 | $35.2M | — | ||
| Q3 25 | $35.1M | $19.6M | ||
| Q2 25 | $35.8M | $21.8M | ||
| Q1 25 | $36.1M | $40.8M | ||
| Q4 24 | $37.0M | — | ||
| Q3 24 | $35.4M | $22.1M | ||
| Q2 24 | $33.3M | $22.5M | ||
| Q1 24 | $33.5M | $45.5M |
净利润EXFYLAB
| Q4 25 | — | — | ||
| Q3 25 | $-2.3M | $-34.7M | ||
| Q2 25 | $-8.8M | $-33.5M | ||
| Q1 25 | $-3.2M | $-26.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-2.2M | $-26.9M | ||
| Q2 24 | $-2.8M | $-45.7M | ||
| Q1 24 | $-3.8M | $-32.2M |
毛利率EXFYLAB
| Q4 25 | 49.2% | — | ||
| Q3 25 | 49.6% | 48.5% | ||
| Q2 25 | 51.9% | 48.8% | ||
| Q1 25 | 50.6% | 48.4% | ||
| Q4 24 | 51.0% | — | ||
| Q3 24 | 51.6% | 54.9% | ||
| Q2 24 | 56.9% | 46.1% | ||
| Q1 24 | 56.5% | 53.1% |
营业利润率EXFYLAB
| Q4 25 | -11.2% | — | ||
| Q3 25 | -6.4% | -168.5% | ||
| Q2 25 | -28.9% | -118.1% | ||
| Q1 25 | -4.1% | -80.8% | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 0.8% | -120.9% | ||
| Q2 24 | 0.7% | -134.5% | ||
| Q1 24 | -5.3% | -132.2% |
净利率EXFYLAB
| Q4 25 | — | — | ||
| Q3 25 | -6.6% | -177.4% | ||
| Q2 25 | -24.6% | -153.7% | ||
| Q1 25 | -8.8% | -63.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -6.2% | -122.0% | ||
| Q2 24 | -8.3% | -203.3% | ||
| Q1 24 | -11.3% | -70.6% |
每股收益（稀释后）EXFYLAB
| Q4 25 | $-0.07 | — | ||
| Q3 25 | $-0.03 | $-0.09 | ||
| Q2 25 | $-0.10 | $-0.09 | ||
| Q1 25 | $-0.03 | $-0.07 | ||
| Q4 24 | $-0.03 | — | ||
| Q3 24 | $-0.02 | $-0.07 | ||
| Q2 24 | $-0.03 | $-0.12 | ||
| Q1 24 | $-0.04 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $63.1M | $129.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $132.7M | $399.7M |
| 总资产 | $186.0M | $539.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXFYLAB
| Q4 25 | $63.1M | — | ||
| Q3 25 | $61.5M | $129.4M | ||
| Q2 25 | $60.5M | $158.6M | ||
| Q1 25 | $59.6M | $150.9M | ||
| Q4 24 | $48.8M | — | ||
| Q3 24 | $39.2M | $210.6M | ||
| Q2 24 | $53.2M | $269.8M | ||
| Q1 24 | $49.3M | $287.1M |
总债务EXFYLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
股东权益EXFYLAB
| Q4 25 | $132.7M | — | ||
| Q3 25 | $135.7M | $399.7M | ||
| Q2 25 | $131.8M | $424.5M | ||
| Q1 25 | $134.7M | $454.6M | ||
| Q4 24 | $128.2M | — | ||
| Q3 24 | $119.9M | $489.3M | ||
| Q2 24 | $114.0M | $510.3M | ||
| Q1 24 | $106.5M | $577.3M |
总资产EXFYLAB
| Q4 25 | $186.0M | — | ||
| Q3 25 | $186.8M | $539.6M | ||
| Q2 25 | $187.1M | $557.0M | ||
| Q1 25 | $189.2M | $579.6M | ||
| Q4 24 | $173.7M | — | ||
| Q3 24 | $176.2M | $681.5M | ||
| Q2 24 | $192.9M | $708.7M | ||
| Q1 24 | $184.8M | $777.7M |
负债/权益比EXFYLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $2.2M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-23.1M |
| 自由现金流率自由现金流/营收 | — | -118.1% |
| 资本支出强度资本支出/营收 | — | 4.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-111.1M |
8季度趋势，按日历期对齐
经营现金流EXFYLAB
| Q4 25 | $2.2M | — | ||
| Q3 25 | $4.2M | $-22.2M | ||
| Q2 25 | $8.9M | $-20.7M | ||
| Q1 25 | $4.8M | $-30.3M | ||
| Q4 24 | $7.4M | — | ||
| Q3 24 | $3.7M | $-27.9M | ||
| Q2 24 | $9.3M | $-39.0M | ||
| Q1 24 | $3.5M | $-62.5M |
自由现金流EXFYLAB
| Q4 25 | — | — | ||
| Q3 25 | — | $-23.1M | ||
| Q2 25 | — | $-22.6M | ||
| Q1 25 | — | $-35.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-30.1M | ||
| Q2 24 | — | $-41.0M | ||
| Q1 24 | — | $-63.3M |
自由现金流率EXFYLAB
| Q4 25 | — | — | ||
| Q3 25 | — | -118.1% | ||
| Q2 25 | — | -103.6% | ||
| Q1 25 | — | -86.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -136.4% | ||
| Q2 24 | — | -182.2% | ||
| Q1 24 | — | -138.9% |
资本支出强度EXFYLAB
| Q4 25 | — | — | ||
| Q3 25 | 0.0% | 4.5% | ||
| Q2 25 | — | 8.7% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | 10.2% | ||
| Q2 24 | 0.0% | 8.6% | ||
| Q1 24 | 0.0% | 1.7% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXFY
暂无分部数据
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
